Merck Sharp + Dohme Corp.

Merck Canada Inc.

Merch Sharp & Dohme Ltd

Kerrie Spencer

Michael D Altman

Jongwon Lim

Alan B Northrup

Michelle R Machacek

Solomon D Kattar

Andrew M Haidle

John Michael Ellis

Yongxin Han

Daniel Guay

Phieng Siliphaivanh

Ryan D Otte

Michael Hale Reutershan

Brandon Mitsuo Taoka

Kaleen Konrad Childers

Anthony Donofrio

Eric Thomas Romeo

Tony Siu

Christian Fischer

Matthew Christopher

Jonathan B Grimm

Satyanarayana Tummanapalli

Adam J Schell

Hua Zhou

Maria Emilia Di Francesco

Yves Ducharme

David Joseph Guerin

Brian M Andresen

Kenneth L Arrington

Sandra Lee Knowles

Jason Burch

Christian Beaulieu

Brandon D Cash

Joel S Robichaud

Bernard Cote

Hyun Chong Woo

Brendan O'Boyle

Dilrukshi Vitharana

Peng Zhang

Neville J Anthony

Amjad Ali

Fang Liu

Thomas Allen Miller

Qun Dang

John S Wai

Kevin J Wilson

Jacques Yves Gauthier

B Wesley Trotter

Jonathan R Young

Lingyun Wu

James Patrick Jewell

John W Butcher

Qiaolin Deng

Liping Wang

Binyuan Sun

Paul A Tempest

David Jonathan Bennett

Corey E Bienstock

Vouy Linh Truong

Yuan Liu

Graham Frank Smith

Rachel Nicola MacCoss

Chaomin Li

Anna A Zabierek

Scott Peterson

Byron Dubois

Kaleen M Konrad

Matthew L Maddess

Jean-Francois Fournier

Denis Deschenes

Marie-Eve Lebrun

Kristina Dupont-Gaudet

Ekundayo Osimboni

Michele R Machacek

Dilrukshi Witharana

Matthew H Maddess

Paul Tempest

Brendan O' Boyle

Kaleen Konrad

Rachel N Maccoss

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

Aryl sulfonamides as BLT1 antagonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer. 

Aryl acylsulfonamides as BLT1 antagonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatoepatitis, metabolic syndrome, atherosclerosis, and cancer. 

The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, X, X, Y, Y, Y, Y, and Rare as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Triazolyl derivatives as Syk inhibitors

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Pyrazolyl derivatives as Syk inhibitors

The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.

Bipyridylaminopyridines as Syk inhibitors

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Aminopyrimidines as Syk inhibitors

Aminopyrimidines as SYK inhibitors

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Inhibitors of janus kinases

Growing community of inventors

Woonsocket, RI, United States of America

Kerrie Spencer